Regenxbio Inc (RGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 170,441 | 83,328 | 90,242 | 112,724 | 470,347 |
| Cost of Goods | 20,298 | 33,567 | 37,213 | 54,545 | 51,833 |
| Gross Profit | 150,143 | 49,761 | 53,029 | 58,179 | 418,514 |
| Operating Expenses | 311,639 | 283,674 | 321,370 | 321,600 | 259,367 |
| Operating Income | -161,198 | -233,346 | -268,128 | -262,876 | 159,980 |
| Interest Expense | 45,008 | 12,659 | 6,862 | 23,254 | 26,277 |
| Other Income | 12,328 | 18,903 | 11,344 | 5,725 | 7,544 |
| Pre-tax Income | -193,878 | -227,102 | -263,646 | -280,405 | 141,247 |
| Income Tax | N/A | N/A | -152 | -84 | 13,407 |
| Net Income Continuous | -193,878 | -227,102 | -263,494 | -280,321 | 127,840 |
| Net Income | $-193,878 | $-227,102 | $-263,494 | $-280,321 | $127,840 |
| EPS Basic Total Ops | -3.76 | -4.59 | -6.02 | -6.50 | 3.01 |
| EPS Basic Continuous Ops | -3.76 | -4.59 | -6.02 | -6.50 | 3.01 |
| EPS Diluted Total Ops | -3.76 | -4.59 | -6.02 | -6.50 | 2.91 |
| EPS Diluted Continuous Ops | -3.76 | -4.59 | -6.02 | -6.50 | 2.91 |
| EPS Diluted Before Non-Recurring Items | -3.76 | -4.59 | -6.02 | -6.33 | 2.91 |
| EBITDA(a) | $-145,583 | $-217,131 | $-250,121 | $-245,255 | $175,386 |